Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Delve Bio’s flagship product "Delve Detect" is a commercially available metagenomic next-generation sequencing test for infectious disease diagnosis using cerebrospinal fluid. It can detect over 68,000 pathogens with a rapid turnaround time of 48 hours. Clinical studies have shown superior diagnostic yield compared to traditional methods; in one study involving over 4,800 patients with suspected CNS infection, the test identified pathogens in 14.4% of samples[5]. The platform also enables viral subtyping and phylogenetic classification from sequence data[1].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Delve Bio.